Drug Trial Radar · NCT06967831
Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells
Last checked: Nov 19, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Mar 1, 2020
Primary completion
Feb 28, 2030
Study completion Feb 28, 2030
Sponsor
- Lead sponsor
- Charite University, Berlin, GermanyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- European Union; German Research Foundation; German Federal Ministry of Education and Research
- First posted
- May 13, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this project, the investigators are using iPSC lines derived from patients with Leigh syndrome that carry mutations in the mitochondrial (mtDNA) and in the nuclear DNA (nDNA) to reprogram them into neural progenitor cells and into dopaminergic neurons. The researchers are using this experimental system to screen FDA (Food and Drug Administration, USA) and EMA (European Medicines Agency) approved drugs for a positive effect on Leigh patient-derived neuronal cells (drug repurposing) using various biochemical, optic, and morphological outcome measures. Confirmed positive hits may be used for compassionate off-label use in Leigh patients when no standard treatment is available.
Conditions
- Leigh Syndrome (Maternally Inherited, MILS)
- Leigh Syndrome (AR, AD, XR)
Interventions
skin biopsyProcedure
Taking a punch skin biopsy of 3 mm diameter under local anesthesia and culturing skin fibroblasts from them.
generation of iPSCsOther
Using cultured skin fibroblasts of the patients, iPSCs will be generated according to standard procedures.
blood drawingDiagnostic test
Drawing blood from a peripheral vein for DNA and RNA isolation. The degree of heteroplasmy (mutation load) for the mtDNA mutation will be determined in the blood DNA.
off-label compassionate drug useDrug
In case the investigators identify a positive hit during drug repurposing with FDA and EMA approved substances, they will offer it as off-label compassionate use to patients for whom no standard treatment is available.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction of the increased mitochondrial membrane potentialTime frame: 1 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Universitätsklinikum Düsseldorf
Düsseldorf, North Rhine-Westphalia, Germany · Recruiting
Charite - Universtaetsmedizin Berlin
Berlin, State of Berlin, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.